|Report Code: PP10191||Report Type: Molecule-Type Pipeline Reports||Available format:|
Recombinant biologic is an entity that includes wide range of therapeutics, such as blood and blood components, vaccines, tissues, gene therapy, and recombinant therapeutic proteins. A biologic can be comprised of protein, nucleic acids, and sugars. Recombinant biologics are the substances that produce similar biological actions as biologics, and are derived from genetically modified microorganisms.
LFB Biotechnologies S.A. is developing LR769 as a recombinant form of factor VIIa for the treatment of congenital hemophilia A and B. F. Hoffmann-La Roche Ltd. is developing obinutuzumab as a glycoengineered, type II, humanized anti-CD20 monoclonal antibody for the treatment of hematological indications. AzurRx BioPharma Inc. is formulating MS1819 as a recombinant lipase for the treatment of exocrine pancreatic insufficiency in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). Pharming Group N.V. is another company developing recombinant biologic therapeutics in its pipeline.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.